Q/C Technologies, Inc. Amortization of Debt Discount (Premium)
Q/C Technologies, Inc. (QCLS) reported Amortization of Debt Discount (Premium) of $608.46 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-31.
Discontinued › Cash Flow › Operating Activities
us-gaap:AmortizationOfDebtDiscountPremium · last filed 2023-03-31
- Q/C Technologies, Inc. amortization of debt discount (premium) for the quarter ending 2021-12-31 was $0.00.
- Q/C Technologies, Inc. amortization of debt discount (premium) for the quarter ending 2021-09-30 was $0.00, a 100.00% decline year-over-year.
- Q/C Technologies, Inc. amortization of debt discount (premium) for the quarter ending 2021-06-30 was $0.00.
- Q/C Technologies, Inc. amortization of debt discount (premium) for the quarter ending 2021-03-31 was $608.46K.
- Q/C Technologies, Inc. amortization of debt discount (premium) for fiscal 2021 was $608.46K, a 48.95% decline from fiscal 2020.
- Q/C Technologies, Inc. amortization of debt discount (premium) for fiscal 2020 was $1.19M.
| Period end | Amortization of Debt Discount (Premium) 3 month | Amortization of Debt Discount (Premium) 6 month | Amortization of Debt Discount (Premium) 9 month | Amortization of Debt Discount (Premium) 9 month as first filed | Amortization of Debt Discount (Premium) 12 month |
|---|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $0.00 derived: sum of 2 quarters · filed 2023-03-31 | $0.00 derived: sum of 3 quarters · filed 2023-03-31 | $608.46K 10-K · filed 2023-03-31 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $0.00 derived: sum of 2 quarters · filed 2022-11-10 | $608.46K 10-Q · filed 2022-11-10 | $264.04K derived: sum of 4 quarters · filed 2022-11-10 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $608.46K 10-Q · filed 2022-08-15 | $264.04K derived: sum of 3 quarters · filed 2022-08-15 | $1.52M derived: sum of 4 quarters · filed 2022-08-15 | |
| 2021-03-31 | $608.46K 10-Q · filed 2022-05-16 | $264.04K derived: sum of 2 quarters · filed 2022-05-16 | $1.52M derived: sum of 3 quarters · filed 2022-05-16 | ||
| 2020-12-31 | -$344.42K derived: 10-K 12 month − 10-Q/A 9 month · filed 2022-03-31 | $913.17K derived: sum of 2 quarters · filed 2022-03-31 | $1.19M 10-K · filed 2022-03-31 | ||
| 2020-09-30 | $1.26M derived: 10-Q/A 9 month − 10-Q 6 month · filed 2021-11-15 | $1.54M 10-Q/A · filed 2021-11-15 | $371.21K 10-Q · filed 2021-11-12 | ||
| 2020-06-30 | $278.69K 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |